Company Overview and News

 
Builders scale down, exit projects amid cash crunch

53m livemint
Squeezed by impatient lenders on one side and angry customers on the other, many property developers are shrinking their businesses or planning to exit altogether. Some of them have avoided new launches for years, focusing instead on completing ongoing projects, selling land and finding partners for development.
503031 PENINLAND GODREJPROP 533207 JPINFRATEC 533150

 
Jaypee Infratech Limited - Corporate Insolvency Resolution Process

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
Jaypee homebuyers’ voting issue resolved with electoral college at 10,000, says IBBI Chief MS Sahoo

2018-10-04 financialexpress
Allaying fears of more than 25,000 homebuyers, Insolvency and Bankruptcy Board of India (IBBI) Chairperson M.S. Sahoo has said all voting related obstacles in Japyee Infratech’s resolution have been removed.
533207 JPINFRATEC

 
Jaypee Infratech Limited - Corporate Insolvency Resolution Process

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
Independent director of Jaypee Infratech ‘Sham Lal Mohan’ resigns

2018-09-17 freepressjournal.in
New Delhi: Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company’s independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Another independent director of Jaypee Infratech resigns; fourth in last one week

2018-09-17 moneycontrol
Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company's independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Jaypee Infratech Limited - Resignation

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
One more independent director of Jaypee Infratech resigns

2018-09-12 moneycontrol
Debt-ridden Jaypee Infratech, which is facing insolvency proceedings,said that its independent director Lalit Bhasin has resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Jaypee Infratech Limited - Resignation

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
ICICI files insolvency plea against Jaiprakash

2018-09-11 freepressjournal.in
New Delhi : Private sector lender ICICI Bank has filed insolvency petition against Jaiprakash Associates before the National Company Law Tribunal (NCLT).
532532 ICICIBANK 533207 JPINFRATEC JIPKY 532174 IBN JPASSOCIAT

 
ICICI Banks files insolvency plea against Jaiprakash Associates

2018-09-10 livemint
New Delhi: Leading private sector lender ICICI Bank has filed insolvency petition against Jaiprakash Associates before the National Company Law Tribunal (NCLT).
JIPKY 532538 532215 MAHABANK SYNDIBANK 533207 AXISBANK UCLQY UBNC AXB IBN JPASSOCIAT UCLQF 532525 ULTRACEMCO AXBKY 532532 532179 AXBA ICICIBANK 532276 CRPKY JPINFRATEC 532174 CORPBANK

 
Jaypee Infratech’s two independent directors resign

2018-09-10 livemint
New Delhi: Jaypee Infratech Ltd, which is facing insolvency proceedings, Monday said that the company’s two independent directors—Keshav Prasad Rau and Basant Kumar Goswami —have resigned.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Jaypee Infratech Limited - Reply to Clarification Sought

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
Jaypee Infratech Limited - Clarification

2018-08-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

 
Jaypee Infratech Limited - Resignation

2018-08-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533207 JPINFRATEC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...